Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Arthur J. Gallagher in the acquisition of the insurance intermediary Proinova
Mandate

Vinge represents Arthur J. Gallagher in the acquisition of the insurance intermediary Proinova

October 17, 2019 M&A

Arthur J. Gallagher & Co. has acquired the insurance intermediary Proinova as a part of the strategic development and expansion in Scandinavia.

Proinova is an expert within insurance solutions in the real estate segment and offers their services of insurance solutions to both groups and individuals. Vinge has previously represented Arthur J. Gallagher & Co. in the acquisitions of the Swedish insurance intermediaries Brim AB and Nordic Försäkring & Riskhantering AB. 

Vinges team consisted of partner Matthias Pannier with associates Marith Welin‑Berger (M&A), Lisa Ullman, Sophia Holm (employment), Paulina Malmberg (regulatory and financial services), Victor Ericsson (tax) and Hedvig Ekdahl (commercial agreements).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025